Fig. 1

Treatment	Number of animals	Duration of graft survival of the transplanted liver (days)	Average (days)	Test value (P[a])
Control	6	10, 11, 11, 11, 12, 12	11.1	
Anti-AILIM antibody (1 mg/kg; IV injection; day 0)	5	10, 10, 11, 12, 13	11.2	
Anti-AILIM antibody (1 mg/kg; IV injection; day 0 and 6)	5	10, 11, 11, 12, 14	11.6	
Anti-AILIM antibody (1 mg/kg; IV injection; day 0, 3, and 6)	7	10, 14, 16, 26, 28, 30*, 30*	>21.9	<0.001
Anti-AILIM antibody (1 mg/kg; IV injection; day 0, 3, 6, 9, and 12)	9	13, 16, 19, 19, 23, 25, 29, 31, 32	23	<0.001
Anti-AILIM antibody (0.3 mg/kg; IV injection; day 0, 3, 6, 9, and 12)	6	12, 12, 14, 17, 25, 27	17.8	<0.001
FK-506 (1 mg/kg; IM injection; day 0)	8	22, 24, 26, 30, 30*, 30*, 19*, 19*	16.5	
Anti-AILIM antibody (1 mg/kg; IV injection; day 0) and FK-506 (1 mg/kg; IM injection; day 0)	8	17, 41, 47, 56, 19*, 19*, 64*, 129*	>49.0	<0.001

a : when compared to the control group *: graft still surviving

Fig. 2

Treatment	Number of animals	Duration of graft survival of transplanted liver (days)	Intermediate value (days)	Test value (Pa)
Control (untreated)	6	10, 11, 11, 11, 12, 12	11	
Anti-AILIM antibody (1mg/kg; IV injection; day 0, 3, 6, 9, and 12)	9	13, 16, 19, 19, 23, 25, 29, 31, 32	23	<0.001
FK-506 (1mg/kg; IM injection; day 0)	8	19, 22, 24, 26, 30, 42, 46, 91	28	<0.001
Anti-AILIM antibody (1mg/kg; IV injection; day 0) and FK-506 (1mg/kg; IM injection; day 0)	9	17, 35, 38, 41, 47, 56, 58, >100, >100	> 44	<0.001
Anti-AILIM antibody (1mg/kg; IV injection; day 0, 3, and 6) and FK-506 (1mg/kg; IM injection; day 0)	2	45, 69	57	

Fig. 3



Anti-AILIM antibody (500 μg)
Control antibody (500 μg)
Untreated group
* p<0.01
Cumulative rate of graft survival
(%)
100
80
60
40
20
0
0
20
40
60
80
100
120
140
Duration of graft survival (days)

Fig. 4




Fig. 5

Treatment	Number of animals	Duration of graft survival of the transplanted heart (days)	Intermediate value (days)	Test value (P)
Control (untreated)	10	5, 5, 5, 6, 6, 6, 6, 6, 6, 6	6	
Isotransplantation / untreated	4	>250, >250, >250, >250	>250	
Allotransplantation / AdLacZ	7	6, 6, 6, 6, 7, 7, 7	6	
Allotransplantation / AdCTLA4-Ig	10	40, 42, 58, 62, 64, 65, 68, 109, 140[a], 140[a]	64	<0.001
Allotransplantation / anti-AILIM antibody	7	5, 5, 6, 6, 6, 6, 6	6	
Allotransplantation / AdCTLA4-Ig+anti-AILIM antibody	5	>250[b], >250[b], >250[a], >250[a], >250[a]	>250	<0.001

a : primary skin transplantation

b : secondary heart transplantation

Fig. 6

Treatment	Number of animals	Skin transplantation (primary)		Heart transplantation (secondary)		Heart transplantation (primary)	
		Rejection	Graft survival	Rejection	Graft survival	Rejection	Graft survival
Allotransplantation / AdCTLA4-Ig	2	2/2	0/2			2/2	0/2
Allotransplantation / AdCTLA4-Ig+anti-AILIM antibody	5	2/2	0/2	0/3	3/3	0/5	5/5